Seer, Inc. (NASDAQ:SEER) Short Interest Update

Seer, Inc. (NASDAQ:SEER) saw a significant increase in short interest in February. As of February 13th, there was short interest totaling 634,111 shares, an increase of 126.6% from the January 29th total of 279,780 shares. Based on an average daily trading volume, of 352,140 shares, the short-interest ratio is presently 1.8 days. Approximately 1.3% of the shares of the stock are short sold. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 352,140 shares, the short-interest ratio is presently 1.8 days.

Seer Stock Down 17.3%

Shares of SEER traded down $0.36 during mid-day trading on Friday, reaching $1.72. 831,259 shares of the company’s stock were exchanged, compared to its average volume of 367,430. Seer has a 52-week low of $1.62 and a 52-week high of $2.41. The company has a market cap of $95.96 million, a price-to-earnings ratio of -1.34 and a beta of 1.63. The company has a 50-day simple moving average of $1.89 and a two-hundred day simple moving average of $2.01.

Seer (NASDAQ:SEER) last announced its earnings results on Thursday, February 26th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. The firm had revenue of $4.20 million during the quarter, compared to the consensus estimate of $4.60 million. Seer had a negative net margin of 443.96% and a negative return on equity of 25.35%. As a group, equities research analysts predict that Seer will post -1.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Seer

Several hedge funds have recently modified their holdings of SEER. Occudo Quantitative Strategies LP acquired a new position in Seer during the second quarter worth approximately $25,000. Quadrature Capital Ltd purchased a new stake in shares of Seer during the 2nd quarter valued at $47,000. Marshall Wace LLP purchased a new stake in shares of Seer during the 4th quarter valued at $85,000. Barclays PLC increased its holdings in shares of Seer by 685.0% during the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after buying an additional 52,982 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new position in shares of Seer in the 4th quarter worth $116,000. 75.20% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Seer

Here are the key news stories impacting Seer this week:

• Positive Sentiment: Q4 EPS beat and improving operating metrics: Seer reported GAAP Q4 EPS of ($0.29), beating consensus by $0.03, with gross margin ~52% and a narrowing net loss vs. prior year — signs of progress on cost reduction. Press Release
• Positive Sentiment: Installed base and scientific validation: Installed base expanded to 82 instruments (67% YoY growth) and customer studies were published in top journals, supporting commercial adoption of the Proteograph platform. Quiver Quant Summary
• Positive Sentiment: Shareholder protections and buyback: Board adopted an NOL preservation plan to protect ~$262M of tax assets (reduces future tax risk) and Seeking Alpha noted a new buyback approval — both can be supportive for long‑term value. NOL Plan Buyback Article
• Neutral Sentiment: Solid cash runway: Seer reported approximately $240.6M in cash, cash equivalents and investments at year‑end, providing runway to execute product development and commercialization plans. Press Release
• Negative Sentiment: Conservative 2026 revenue guidance — big miss vs. Street: Management guided FY‑2026 revenue of $16.0–$18.0M vs. consensus ~ $22.1M, implying only ~3% growth at the midpoint versus 2025 — the primary catalyst for the share decline. Guidance Press Release
• Negative Sentiment: Revenue miss and continued losses: Q4 revenue was $4.2M (below some analyst estimates of $4.6M) and FY‑2025 net loss remained sizable ($73.6M), highlighting ongoing path‑to‑profitability risk. Press Release
• Negative Sentiment: Demand headwinds and market skepticism: Management cited customer budget pressures and NIH funding uncertainty; short interest jumped ~126.6% in February, indicating increased bearish positioning. Quiver Quant / Short Interest

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on SEER shares. Wall Street Zen upgraded Seer to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.